financetom
LH
financetom
/
Healthcare
/
LH
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Laboratory Corporation of America HoldingsLH
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.

It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings.

In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access.

It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories.

The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Latest News >
OMS Energy Technologies Prices 3.7 Million Share IPO at $9 per Share
OMS Energy Technologies Prices 3.7 Million Share IPO at $9 per Share
May 26, 2025
10:05 AM EDT, 05/13/2025 (MT Newswires) -- OMS Energy Technologies ( OMSE ) said Tuesday it priced its initial public offering of about 3.7 million ordinary shares at $9 per share. The total base offering size is $33.3 million, assuming the underwriters don't exercise their 45-day option to buy up to 555,555 additional ordinary shares at the IPO price, the...
Bank of America to open more than 150 new branches by 2027
Bank of America to open more than 150 new branches by 2027
May 26, 2025
May 13 (Reuters) - Bank of America ( BAC ) plans to open more than 150 new branches by the end of 2027, it said on Tuesday, as part of the lender's efforts to expand its physical presence across the United States. The bank will open 40 new branches this year, with an additional 70 sites planned for 2026, it...
GM, LG to make new, lower-cost cells for future EVs
GM, LG to make new, lower-cost cells for future EVs
May 26, 2025
DETROIT (Reuters) -General Motors ( GM ) and battery partner LG Energy Solution are planning to start commercial production of lower-cost cells for future electric vehicles at a U.S. facility starting in 2028, the companies said on Tuesday.  The cells will have a lithium manganese-rich (LMR) chemistry, which GM says is lower cost than the nickel-rich cells used today, but...
Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy
Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy
May 26, 2025
10:03 AM EDT, 05/13/2025 (MT Newswires) -- Bright Minds Biosciences ( DRUG ) said Tuesday that its BMB-101 showed a complete elimination of drop attacks in the DBA/2 mouse model of epilepsy. Notably, BMB-101 achieved 100% survival in the DBA/2 model, reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest, Jan Torleif Pedersen, the company's chief science officer, said. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved